| Symbol | AIXC |
|---|---|
| Name | QUALIGEN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2042 CORTE DEL NOGAL,SUITE B, CARLSBAD, California, 92011, United States |
| Telephone | +1 760 918-9165 |
| Fax | — |
| — | |
| Website | https://www.qlgntx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001460702 |
| Description | Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. Additional info from NASDAQ: |
AIxCs RoboShare Makes U.S. Robot-Sharing History as Seven Robots Share the Stage with DU$TY and Big
Read moreAIxC Launches RoboShare & Co. North American Dealer Program as First Flywheel Case, Secures One-year $33,000 Robot Rental Order and Expands A Signed FFAI Robot Order to 23 Units
Read moreAIxCrypto Provides Additional Context on Schedule 14C Filing and Disciplined Capital Strategy to Advance RoboShares Next Stage of Growth
Read moreAIxCs RoboShare Secures New Short- and Long-Term Orders, Plans to Build North Americas Largest and Most Diverse Robot-Sharing Platform
Read moreNew Form S-1/A - AIxCrypto Holdings, Inc. <b>Filed:</b> 2026-08-18 <b>AccNo:</b> 0001493152-26-039049 <b>Size:</b> 564 KB
Read moreAIxC Announces Strategic Pivot to Physical AI and Robotic Operations Commercialization; RoboShare Completes First Paid Commercial Order
Read more(99% Neutral) QUALIGEN THERAPEUTICS, INC. (AIXC) Announces Business Combination
Read more(30% Negative) QUALIGEN THERAPEUTICS, INC. (AIXC) Reports Q3 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06086522 | Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced … | Phase1 | Solid Tumor | Recruiting | 2023-11-01 | 2026-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| QN-302 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06086522 |